APGE | Apogee Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	45.51 - 48.42
52 Week Range	25.85 - 72.29
Beta	1.24
Implied Volatility	54.06%
IV Rank	48.74%
Day's Volume	566,386
Average Volume	458,207
Shares Outstanding	58,513,196
Market Cap	2,791,664,581
Sector	Healthcare
Industry	Biotechnology
IPO Date	2023-07-14

Valuation
Profitability
Growth
Health
P/E Ratio	-19.63
Forward P/E Ratio	N/A
EPS	-2.43
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	91
Country	USA
Website	APGE

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

*Chart delayed

Analyzing fundamentals for APGE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see APGE Fundamentals page.

Watching at APGE technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on APGE Technicals page.